




Product Pipeline of Toyama Chemical

February 26, 2008

FORWARD-LOOKING STATEMENTS

Forward-looking statements such as those relating to earnings forecasts and other projections contained in this material are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

Current State of New Drug Development



Outline of Drugs under Development



Development number	Area of effectiveness	Characteristics
T-817MA	Alzheimer's disease treatment agent	In addition to inhibiting neural cell death, this drug helps promote neurite growth. It also shows potency in animal models of AD.
T-5224	Rheumatoid arthritis treatment agent	By inhibiting the transcription factor AP-1, this drug suppresses inflammation and joint destruction, and it is expected to become a fundamental treatment for rheumatoid arthritis.
T-705	Antiviral agent	An anti-influenza drug that acts on the RNA polymerase of the virus to prevent reproduction. This drug is expected to be effective against type A(H5N1) avian flu.
T-2307CLH	Antifungal agent	This drug uses a new mechanism differing from that of previous drugs and has a wide spectrum of effectiveness as an antifungal agent. It is also effective against drug-resistant strains.



We will use leading-edge, proprietary technologies to provide top-quality products and services that contribute to the advancement of culture, science, technology and industry, as well as improved health and environmental protection in society. Our overarching aim is to help enhance the quality of life of people worldwide.

FUJIFILM Holdings Corporation